These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33244248)

  • 21. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
    Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
    Clin Ther; 2003 Feb; 25(2):472-84. PubMed ID: 12749508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM).
    Kesavadev J; Pillai PBS; Shankar A; Krishnan G; Jothydev S
    Endocr Connect; 2017 Nov; 6(8):748-757. PubMed ID: 28982699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Sitagliptin on Pancreatic Beta-Cells in Type 2 Diabetes With Sulfonylurea Treatment: A Prospective Randomized Study.
    Sato A; Takei M; Hiramatsu K; Takeda T; Miyamoto T; Yamazaki M; Sato Y; Komatsu M
    J Clin Med Res; 2019 Jan; 11(1):15-20. PubMed ID: 30627273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fixed-dose combinations in type 2 diabetes - role of the canagliflozin metformin combination.
    Fleming JW; Fleming LW; Davis CS
    Diabetes Metab Syndr Obes; 2015; 8():287-94. PubMed ID: 26150733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus.
    Qiu R; Capuano G; Meininger G
    J Clin Transl Endocrinol; 2014 Jun; 1(2):54-60. PubMed ID: 29159083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial.
    Sezai A; Tanaka A; Imai T; Kida K; Sekino H; Murohara T; Sata M; Suzuki N; Node K;
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
    Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
    J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
    Müller-Wieland D; Kellerer M; Cypryk K; Skripova D; Rohwedder K; Johnsson E; Garcia-Sanchez R; Kurlyandskaya R; Sjöström CD; Jacob S; Seufert J; Dronamraju N; Csomós K
    Diabetes Obes Metab; 2018 Nov; 20(11):2598-2607. PubMed ID: 29947099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study.
    Osonoi T; Tamasawa A; Osonoi Y; Ofuchi K; Katoh M; Saito M
    Diabetes Ther; 2019 Dec; 10(6):2045-2059. PubMed ID: 31506889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients.
    Jeon HJ; Oh TK
    Diabetes Metab J; 2011 Oct; 35(5):529-35. PubMed ID: 22111045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Weiss R; Rosenstock J; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B
    Diabetes Ther; 2015 Sep; 6(3):289-302. PubMed ID: 26081793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
    Hollander P; Liu J; Hill J; Johnson J; Jiang ZW; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Ther; 2018 Feb; 9(1):193-207. PubMed ID: 29282633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
    Lee SH; Gantz I; Round E; Latham M; O'Neill EA; Ceesay P; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    BMC Endocr Disord; 2017 Nov; 17(1):70. PubMed ID: 29110647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
    Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
    Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea.
    Kim HS; Kim DM; Cha BS; Park TS; Kim KA; Kim DL; Chung CH; Park JH; Jang HC; Choi DS
    J Diabetes Investig; 2014 Nov; 5(6):701-8. PubMed ID: 25422771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.